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Introduction
Primary chest wall tumor is rare and represents about
5% of all thoracic neoplasms.1–3 It encompasses
tumors of various origins, including bone and carti-
lage, soft tissue such as muscle, vessel, nerve, and
even some hematologic diseases.1,4,5 Only 8% of 
primary bone tumors occur in the chest wall.6 The
clinical presentation of primary chest wall tumor is
nonspecific. It is sometimes difficult to make an 
accurate diagnosis before histologic examination.
Although the technique of chest wall reconstruction
has evolved and aggressive resection is now safe and
reliable,4,5,7–9 wide resection is not applicable to all
kinds of primary chest wall tumors. The dilemma met in
precise preoperative diagnosis complicates the treat-
ment planning. Here, we retrospectively reviewed our
experience in managing 62 patients with primary
chest wall tumors from 1991 to 2004. This study puts
emphasis on the demographic presentation and the
approaches in the management of primary chest wall
tumors.
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Methods
From 1991 to 2004, 62 patients with the diagnosis of
primary chest wall tumors were enrolled in this study.
The definition of primary chest wall tumors is neo-
plasms arising from structures that support the thorax,
including bone, cartilage, and associated soft tissue.
Patients with chest wall lipoma, metastatic chest wall
lesions, chest wall invasion from nearby malignancy
(breast cancer, lung cancer, mesothelioma), chest wall
infection (e.g. cold abscess by Mycobacterium tubercu-
losis), and chest wall inflammation (e.g. Tietze’s syn-
drome) were excluded. The medical charts of 62
patients were retrospectively reviewed. Clinical data
including history, gender, age, clinical symptoms, imag-
ing findings (chest X-ray [CXR], computed tomogra-
phy [CT], bone scan), tumor size, location, hospital
stay, operation methods, pathology reports, and out-
come were collected. Pathologic diagnosis was made
by nonexcision biopsy (fine needle aspiration and/or
incision biopsy) or histologic examination from surgi-
cal specimens. Origins of neoplasms were classified into
osseous and cartilaginous, soft tissue (e.g. muscle,
vessel, peripheral nerve, fibrous tissue), and hemato-
logic (e.g. lymphoma, plasmacytoma). The follow-up
period was determined from the date of admission to
the latest date of medical record or telephone contact.
Outcome was recorded as with or without recurrence
or metastasis. Two patients were lost to follow-up 
and were not included in the outcome analysis. The
mean follow-up period was 42 months (range, 1–152
months) among the remaining 60 patients. The 
follow-up rate in this study was 96.8%.
Continuous variables were expressed as mean ± SD.
Statistical analysis was performed using Fisher’s exact
test and χ2 test for categorical variables, and t and
ANOVA tests for continuous variable comparison. A
value of p < 0.05 was considered statistically significant.
Results
Tables 1 and 2 show the demographic data and
pathologic diagnosis of 62 patients with primary
chest wall tumors. Their mean age was 51.18 ± 19.97
years (range, 11–84 years). There were 37 males and
25 females. Thirty-one patients had benign tumors
Table 1. Demographic data of 62 patients with primary chest
wall tumor
n (%)
Benign/malignant 31/31
Sex (male/female) 37/25
Age (yr) 51.18 ± 19.97
Tumor size (cm) 7.84 ± 5.35
Symptoms
None 9 (14.5)
Pain 25 (40.3)
Mass 34 (54.8)
Cough 3 (4.8)
Dyspnea 1 (1.6)
Neurologic 3 (4.8)
Treatment
Medical treatment 6 (9.7)
Surgical excision 30 (90.3)
Table 2. Pathologic diagnosis of 62 patients with primary chest
wall tumor
n
Benign
Bone and cartilaginous
Chondroma 3
Chondroblastoma 1
Chondromatous hamartoma 1
Chondromyxoid fibroma 1
Fibrous dysplasia 2
Giant cell tumor 1
Oseochondroma 3
Soft tissue
Angiolipoma 1
Cavernous lymphangioma 1
Fibrolipoma 1
Fibrous tumor 4
Ganglioneuroma 2
Hemangioma 1
Leiomyoma 2
Schwannoma 5
Neurofibroma 2
Malignant
Bone and cartilaginous
Chondrosarcoma 7
Osteosarcoma 2
Soft tissue
Dermatofibrosarcoma protuberance 3
Epithelioid angiosarcoma 1
Hemangiopericytoma 1
Leiomyosarcoma 1
Liposarcoma 1
Malignant fibrous histiocytoma 2
Neuroendocrine tumor 1
Sarcomatoid carcinoma 1
Hematologic disease
Lymphoma 9
Plasmacytoma 2
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62 primary chest wall tumors
26 nonexcision biopsy 36 patients
21 positive results 5 negative results
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tissue tumors
6 chemotherapy
or radiotherapy
Figure 1. Management algorithm of 62 patients with primary chest wall tumors. MFH = malignant fibrous histiocytoma.
and 31 had malignant tumors. The mean tumor diam-
eter at the greatest dimension was 7.84 ± 5.35 cm. The
most common clinical symptoms were palpable mass
(54.8%) and pain (40.3%). In benign tumors, 12 neo-
plasms were of bone and cartilaginous origin and 19
were of soft tissue origin. In primary malignant
tumors, 9 neoplasms were of bone and cartilaginous
origin, 11 of soft tissue origin, and 11 of hematologic
disease origin. Twenty-six patients received nonexci-
sion biopsy for the initial presentation. Definite diag-
nosis was obtained in 21 of these 26 patients (80.7%).
Five patients with negative pathologic result subse-
quently underwent surgical excision. Thirty-six patients
received surgical intervention initially for the removal
of their chest wall tumors. Among 56 patients who
received surgical treatment, the chest wall defect was
too large to be repaired by muscle flap in 12 patients.
Mesh repair was performed in 12 patients. Surgical
margin was free of tumor in all patients who underwent
excision. The management algorithm of our patients in
this study is presented in Figure 1.
Table 3 shows the data comparison between patients
with benign and malignant primary chest wall tumors.
Patients with malignant chest wall tumors were signifi-
cantly older than those with benign tumors (59.94±
17.05 years vs. 42.42±19.01 years, p<0.001). Mean
tumor diameter was also significantly greater in malig-
nant tumors compared to benign tumors (9.17 ±
5.36 cm vs. 6.52 ± 5.06 cm, p = 0.04). Nine of 31
patients (29.0%) with benign chest wall tumor were free
of symptoms whereas patients with malignant chest wall
tumors were all symptomatic (p=0.002). Table 4 shows
the data comparison among patients with different 
origins of chest wall tumor. Patients with hematologic
origin of chest wall tumor were more male predominant
than those with tumors of bone or soft tissue origins 
(p=0.03). Patients with tumors of hematologic disease
origin (66.36±14.79 years) were also older than those
with tumors of bone and cartilage origin (50.05±21.50
years), and soft tissue origin (46.40±18.23 years, p=
0.01). Presence of symptoms and mean tumor size were
not different among the 3 tumor origins. Tumor recur-
rence or metastasis was found in 10 patients, including
5 chondrosarcomas, 1 lymphoma, 1 plasmacytoma, 1
leiomyosarcoma, 1 osteosarcoma, and 1 sarcomatoid
carcinoma. All recurrences or metastases developed in
Table 3. Comparison between patients with benign and malignant chest wall tumors
Benign (n = 31) Malignant (n= 31) p
Sex (male/female) 16/15 21/10 0.3
Age (yr) 42.42± 19.01 59.94± 17.05 < 0.001*
Presence of symptoms 22 31 0.002*
Presence of pain 10 15 0.3
Tumor size (cm) 6.52 ± 5.06 9.17 ± 5.36 0.04*
*p < 0.05. Fisher’s exact test for sex, presence of symptoms, and presence of pain comparison. Student’s t test for age and size comparison.
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the first 2 years after treatment and 70% were within
the first postoperative year. Of 10 patients, 3 died of
disease-related complications (at 3, 9, and 25 months
after diagnosis), 3 died of unrelated conditions, and 4
were still alive with follow-up periods of 2, 14, 70,
and 159 months, respectively.
Chondrosarcoma and lymphoma were the 2 most
common types of malignant chest wall tumors in our
series. All patients with chest wall chondrosarcoma
received surgical excision. Recurrence developed in 5
of 7 patients at 3, 5, 6, 7, and 20 months after opera-
tion. Four of 5 patients received repeated surgical exci-
sion and 3 had radiotherapy. The other patient with
superior vena cava (SVC) syndrome died due to respi-
ratory failure. This was the only disease-related mor-
tality in the chondrosarcoma group in our series. All
cases of chest wall lymphoma were of diffuse large B
cell type in our study. Five of 9 patients with chest
wall lymphoma received chemotherapy. The regimens
included cyclophosphamide, doxorubicin, vincristine,
and prednisolone (CHOP), cyclophosphamide, vin-
cristine, and prednisolone (COP), and cyclophos-
phamide, epirubicin, vincristine, and prednisolone
(CEOP). Two of 5 patients had other organ involve-
ment. Regression of chest wall tumors after chemother-
apy was noted in 4 of them. Two of 4 patients died at
7 and 10 months after diagnosis due to pneumonia and
sepsis, respectively. Another patient who had recurrence
of lymphoma received further chemotherapy and radio-
therapy for multiple bone metastasis subsequently.
He died of pneumonia at 49 months after diagnosis.
The other patient with isolated chest wall lymphoma
improved after chemotherapy and is currently free 
of disease. Only 1 patient with chest wall lymphoma
was refractory to chemotherapy. This patient died at 
7 months after diagnosis because of chemotherapy-
related complications. The other 4 patients with iso-
lated chest wall lymphoma received surgical excision
followed by adjuvant chemotherapy, and they were
without recurrence at 36, 38, 52, and 111 months
after treatment.
Discussion
Primary tumors of the chest wall are uncommon;
therefore, the experience in managing this kind of
tumor is limited in each medical unit. In clinical prac-
tice, it is difficult to diagnose from clinical features,
radiologic examination, or even aspiration biopsy.
Most patients with primary chest wall tumor received
excision biopsy or radical resection for the chest wall
tumor before the diagnosis was obtained.1 Of the 
157 patients who presented with chest wall mass, only
62 patients had primary chest wall tumor and were
included in our study. It has been reported that pri-
mary chest wall tumors occur mostly in the 5th and
6th decades of life with equal gender distribution and
possibility of benign or malignancy.1,2,5,7,10–14 The
mean age was 51.18 years in our study and patients
with malignant chest wall tumors were significantly
older than those with benign tumors. The male to
female ratio was about 1:1, although slight male pre-
dominance was found in the malignant tumor group.
The ratio of benign to malignant primary chest wall
tumors was 1:1 in our series. The most frequent symp-
toms in patients with primary chest wall tumors were
palpable mass and pain.8 Neurologic symptoms such
as muscle weakness and brachial plexus neuropathy
have also been reported.12,13 In our study, 29.0% of
patients with benign primary chest wall tumors were
asymptomatic, whereas all patients with malignant
neoplasm were symptomatic. Among the patients with
primary chest wall tumors of bone and cartilaginous
origin, rib was the most common source.1,5,10 In our
series, 5 primary chest wall tumors arose from the
sternum. Four of them (80%) were malignant. This
result is similar to previous reports in the literature
that neoplasms from the sternum, though rare, are
usually malignant.6,8
Imaging studies, including CXR and CT, are use-
ful in determining the extent of tumor invasion, sur-
gical treatment planning, and follow-up evaluation of
patients with chest wall tumors. However, imaging
Table 4. Comparison among patients with different origins of chest wall tumors
Bone and cartilage (n = 21) Soft tissue (n = 30) Hematologic disease (n = 11) p
Sex (male/female) 13/8 14/16 10/1 0.03
Age (yr) 50.05 ± 21.50 46.40 ± 18.23 66.36 ± 14.79 0.01*
Benign/malignant 12/9 20/10 0/11 0.000*
Tumor size (cm) 7.17 ± 4.95 7.82 ± 5.79 9.16 ± 5.05 0.61
Presence of symptoms 19 23 11 0.12
Presence of pain 6 14 5 0.42
*p < 0.05. χ2 exact test for sex, benign or malignant, presence of symptoms, and presence of pain comparison. ANOVA test for age and size comparison. Patients
in hematologic origin group are significantly older than in bone/cartilage origin group (p = 0.024) and soft tissue origin group (p = 0.004) by post hoc test.
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features of chest wall tumors are nonspecific.9,15 Soft
tissue mass, bone destruction, calcification, and bone
deformity are frequently described, but are not diag-
nostic of malignancy. Although some typical features
can be linked to certain types of neoplasms, such as
the presence of phleboliths and vascular enhancement
in hemangioma, target-like appearance on magnetic
resonance images (MRI) in neurofibroma, well-defined
cortical and medullary continuity in osteochondroma,
fusiform expansion and ground glass matrix in fibrous
dysplasia, expansile osteolytic lesion with fluid–fluid
levels in giant cell tumors, presence of chondroid 
or osteoid matrix in osteosarcoma, and diffuse oste-
olytic change with a soft tissue rib mass in multiple
myeloma,16,17 it is still difficult to make the diagnosis
of chest wall tumors or to differentiate benign from
malignant chest wall tumors from imaging findings.
Osteochondroma, chondroma, and fibrous dyspla-
sia constitute 60–70% of all benign chest wall tumors,
whereas chondrosarcoma is the most common pri-
mary malignant chest wall tumor.3,12 In our study,
chondroma, osteochondroma, and schwannoma were
the most common benign chest wall tumors. All these
patients received surgical excision and recovered well.
Chondrosarcoma and chest wall lymphoma were the
most frequent malignant chest wall tumors in our
series. All 7 patients with chondrosarcoma received
surgical excision. The recurrence rate after excision
was 62.5%. One patient with recurrence developed
pleural effusion and SVC syndrome and died of dis-
ease. Briccoli et al15 reported 16 cases with chon-
drosarcoma and found recurrence in 6 of 16 patients
after wide excision and that it may occur as late as 68
months after operation. In our study, 1 patient experi-
enced tumor recurrence at 5, 17, 23, 47, and 71
months after the first excision. Repeated excisions
and radiotherapy were carried out. This patient is still
alive and under regular follow-up. Consistent to other
reports, our experience indicates that patients with
chest wall chondrosarcoma are at high risk of tumor
recurrence.10,15 For chondrosarcoma, 2 peak periods
of prevalence have been identified—at less than 20
years of age and at more than 50 years of age. Most
frequently, they are found along the upper 5 ribs.
Bone destruction, irregular contours, and intratu-
moral mineralization are characteristics on CXR. CT
scan is more sensitive for the delineation of chondroid
matrix calcifications. MRI usually shows heteroge-
neous contrast enhancement.17 Wide excision and
careful postoperative evaluation are mandatory for
these patients.
The role of fine needle aspiration or nonexcision
biopsy for the diagnosis of primary chest wall tumor is
controversial.5,9,12,13 Caution is warranted when using
fine needle biopsy as a diagnostic modality since diag-
nosis by cytologic specimen is sometimes unsatisfac-
tory.18 Wrong diagnosis due to inadequate tissue
specimen may even lead to less than optimum treat-
ment and worse prognosis.19 Meanwhile, the risk 
of tumor implantation makes fine needle biopsy an
unpopular tool in the diagnosis of primary chest wall
tumors.4,7 Some authors suggest that all patients with
primary chest wall tumors should receive at least exci-
sion biopsy, whereas those with high suspicion of
malignancy should receive wide radical resection or
subsequent resection for safe margin.1,3–5,7,9,12–14 Non-
excision biopsy should be reserved for those with 
suspicion of metastatic or hematologic disease, in
whom aggressive surgical resection is less benefi-
cial.3,5,7–9,11,20,21 In our studies, 26 patients received
nonexcision biopsy for initial diagnosis. Definite diag-
nosis was obtained in 21 of these 26 patients.
Whether or not patients with primary chest wall
lymphoma should receive surgical resection is contro-
versial. Lymphoma with chest wall involvement is not
uncommon. However, isolated primary chest wall
lymphoma is not frequently seen.22,23 In Ryan et al’s
series,7 2 patients with chest wall lymphoma were
found during a 5-year period. One of them received
surgical resection and was free of disease after 49
months. In our study, the clinical outcome was poor in
5 of 9 patients with chest wall lymphoma who received
chemotherapy after diagnosis, which might be related
to multiple organ involvement and chemotherapy tox-
icity. The other 4 patients with solitary chest wall lym-
phoma received surgical excision followed by adjuvant
chemotherapy. These patients remained free of disease
after a mean follow-up period of 84 months. Although
the primary treatment of choice for lymphoma with or
without chest wall involvement is chemotherapy, sur-
gical intervention can be considered in some selected
patients, especially those with solitary chest wall lym-
phoma without other organ involvement.
In summary, our limited experience in the man-
agement of primary chest wall tumors showed that
patients with malignant neoplasms were older than
those with benign tumors. The mean size of malignant
tumors was larger than that of benign tumors. Absence
of symptoms was more frequently seen in those with
benign than malignant primary chest wall tumors.
Wide excision and careful postoperative evaluation are
mandatory for patients with chest wall chondrosar-
coma who are at high risk of tumor recurrence after
surgical resection. Adequate surgical resection remains
the treatment of choice for patients with primary
chest wall tumors. Nonexcision biopsy should be
J Chin Med Assoc • August 2006 • Vol 69 • No 8382
P.K. Hsu, et al
reserved for patients with a past history of malig-
nancy, suspicion of hematologic disease, and with
high operative risk. For patients with isolated chest
wall lymphoma, surgical resection followed by
chemotherapy can be considered to obtain a better
outcome.
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